ISGlobal Barcelona Institute for Global Health

SPECIFIC AND TECHNICAL CONDITIONS FOR RECRUITMENT OF THE PRELIMINARY AUDIT SERVICE / GAP ANALYSIS

(File #8/2018)

I. PURPOSE

The present document (the "Pliego") is intended to contract the preliminary / GAP ANALYSIS for an IND application at FDA for the use of high-dose ivermectin to reduce malaria transmission.

All the technical specifications detailed in the Specifications are considered of minimum requirements and do not exclude any other necessary requirements for the compliance of the purpose of the service contracted.

II. CONTENT OF THE WORK

Ivermectin as a complementary tool to reduce malaria transmission, Strategic assessment / Gap analysis for pursuing an IND application through FDA's 505(b)(2) using an experimental high dose.

Scope of work

ISGlobal – Barcelona Institute for Global Health is a research centre in international health which ultimate goal is to help to close the gaps in health disparities between and within different regions of the world. For this reason, we leverage on knowledge generation (research), transmission (training) and application (policy and global development). ISGlobal is a WHO Collaborative Center for Malaria Elimination and Eradication.

One of ISGlobal's research lines is the potential use of drugs (particularly ivermectin) that administered to humans and/or livestock reduce the live span of mosquitoes feeding on treated individuals, potentially contributing to reduce malaria transmission if distributed at community level at the appropriate time. For this, ivermectin would be used at a dose/regimen that is higher than currently approved.

ISGlobal is looking for an experienced consultant to conduct a strategic analysis for the regulatory repurposing of ivermectin. We are particularly interested in pursuing the FDA 505(b)(2) pathway.

The key deliverable is a strategic assessment report including at least:

- Toxicology assessment of the proposed dose
- Regulatory Strategy
- Clinical Strategy
- Clinical Pharmacology Strategy
- Nonclinical Strategy
- CMC assessment

III. PERSON RESPONSIBLE FOR THE CONTRACT

ISGlobal will appoint a person responsible for relations with the consultant group (The "Contract Administrator"), who will assure the necessary coordination with the staff of the entity and that will channel communications.

IV. MANAGEMENT OF WORK AND QUALITY CONTROL

ISGlobal and the consultant will establish by common agreement a calendar of communications that will consist of at least fortnightly calls to evaluate the progress of work. Regardless these scheduled calls, the Contract Administrator and the consultants may meet at any time if any of the two parties considers appropriated, depending on the development of the works hired.

At any meeting, the responsible person may decide to bring additional participants from ISGlobal if it is considered convenient.

V. REQUIRED QUALIFICATIONS

- Proven track record of successfully conducted INDs preparations using the FDA 505(b)(2) pathway. Candidates with more than 10 successful INDs will be given preference.
- Capacity to conduct a multidisciplinary approach including but not limited to PK modelling, safety and commercial assessment.
- Experience with international projects
- Track of regular interaction with FDA

VI. PERIOD OF EXECUTION AND DELIVERY OF THE REPORT

The execution of the works will be carried out in a maximum period of 12 weeks.

VII. ESSENTIAL CONTRACTUAL OBLIGATIONS

Essential obligations of the successful bidder will be as follows:

a) Guarantee absolute confidentiality of the documentation received, taking the due diligence not to disclose it, or use it in any way other than the purpose of this contract. Failure to comply with this obligation will automatically imply termination of the contract and will result in a claim by ISGlobal for damages that may have been inflicted.

b) Guarantee and take responsibility for the technical quality of the works and services that develops and the consequences that may occur, by ISGlobal or for third parties, as a consequence of omissions, errors, inadequate methods or incorrect conclusions in the execution of the contract.

c) To carry out a strict follow-up in carrying out the work of the report audit.

d) Deliver the works and reports hired in the manner and terms provided in the Bidding Document.

VIII. CONTRACT PERIOD

The duration of the contract will be 16 weeks

The estimated starting date of the contract is May 15, 2018.

IX. BUDGET, PRICE AND ESTIMATED VALUE OF THE CONTRACT

The contract budget amounts to the maximum amount of

USD 95,000 exempt bidders or EUR 64.305,00 (excluding VAT) for non-exempt bidders

The amount awarded will not exceed this budget in any case.
The price of the contract, consequently, will be that to which it rises plus the corresponding Value Added Tax, in the case of non-exempt bidders, which must be included in the separate item.

The estimated value of the contract for the purpose of determining the procedure awarding, advertising and competition of the contracting authority, is

USD 95,000 exempt bidders or EUR 64.305,00 (excluding VAT) for non-exempt bidders

X.CIVIL LIABILITY POLICY

The company that is awarded the contract commits to have throughout the validity of the contract of a liability policy with coverage minimum of € 500,000.- per claim

XI. ADVERTISING

The present contract will be published by announcement in the Contracting Profile of the entity on the website: www.isglobal.org

XII. PLACE AND DATE OF SUBMISSION OF PROPOSALS

The economic proposals must be submitted by email to the address **licitaciones@isglobal.org**.

The deadline for submitting proposals will end on May 9th, 2018 at 12:00.

XIII. LEGAL SYSTEM OF THE CONTRACT

The contract is considered a private contract and is subject to private law, governed by this Schedule, by the contract and documentation attached, and in everything not provided by the applicable civil and commercial legislation.

XIV. EXPENDIENT OF RECRUITMENT, AWARD PROCEDURE OF THE CONTRACT AND DOCUMENTATION TO BE PROVIDED TENDERS

The contracting of the referred services will be awarded by the procedure envisaged in Section IX of the Internal Contracting Instructions of the entity. From the day of publication of the tender notice, interested companies can obtained through the contractor's profile on the website www.isglobal.org the necessary documentation to prepare proposals.

XV. PAYMENT METHOD

Payment will always be made upon reception of an invoice and no later than 30 days of invoice date by bank transfer:

Upon Sponsor signing this Service Agreement 45%
Upon the delivery of the draft Strategic Assessment Report 40%
Upon the delivery of the final Strategic Assessment Report 15%

Barcelona, April 24, 2018

ISGlobal Barcelona Institute for Global Health

ANNEX
TECHNICAL REPORT

1. Project Background

ISGlobal is developing an experimental ivermectin dose, intended for use in the prevention of malaria in mass drug administration.

The ivermectin-treated individual receives no immediate benefit in terms of malaria), but biting mosquitoes die, the anticipated result of which is a potential reduction in malaria transmission at community level. This is expected to result in a potential 'delayed' benefit for the individual. Additional direct benefits include treatment of head lice, scabies and some intestinal helminths.

There is a precedent for which the FDA Center for Biological Evaluation and Research (CBER) has evaluated a malaria transmission-blocking vaccine with only a delayed benefit to the individual, similar to the Sponsor's proposed dose. If the Center for Drug Evaluation and Research (CDER) views the Sponsor's product as having a delayed benefit, it is anticipated that CDER will evaluate the Sponsor's product as a drug.

ISGlobal requests that the consultant assess the dose's regulatory viability of approval under the 505(b)(2) pathway; and conducts an analysis of the clinical, clinical pharmacology, and nonclinical components required for the product development and 505(b)(2) approval that may be missing or incomplete/inadequate in ISGlobal's intended development program.

The Strategic Assessment under this Service Agreement will focus on clinical, clinical pharmacology, and nonclinical issues. A basic CMC manufacturing plan will be proposed. The Assessment will not include commercial potential assessment.

2. Tasks

Task 1: Research and Analysis

The consultant will gather the necessary clinical and regulatory information. Potential sources from which this information will be obtained include:

- Information from ISGlobal
- Published scientific literature
- Approved product labelling
- FDA Center for Drug Evaluation and Research (CDER) and Center for Biological Evaluation (CBER) Websites
- Freedom of Information requests (Summary Basis of Approval), Monographs
- Federal Register (1936 to present)
- World Wide Web

Task 2: Prepare Strategic Assessment Report Included

The Report will include:

• Regulatory Strategy – Proposed regulatory plan and timeline for product development.

• Clinical Strategy – Evaluation of the available clinical data and assessment of what additional clinical data/studies may be required, if any.

• Clinical Pharmacology Strategy – Evaluation of need for clinical pharmacology and biopharmaceutics studies that may be required for approval, if any.

• Nonclinical Strategy – evaluation of the available nonclinical data and an assessment of what additional nonclinical data/studies may be required, if any.

• CMC –basic manufacturing plan proposed.

ANNEX 2
ECONOMIC PROPOSAL FOR THE CONTRACTING OF THE SERVICE OF PRELIMINARY AUDIT / GAP ANALYSIS

Mr. [.], With address at [.] Street [.] Núm. [.], Aware of the announcement published in the Profile of the Contractor of the Private Foundation Institute of Global Health Barcelona and the conditions and requirements that are required for the award of the service of strategic assessment / gap analysis, undertakes, on behalf of the company it represents, to perform them strictly subject to the aforementioned requirements and conditions, for the amount of [insert economic offer clearly in letters and numbers, with VAT excluded], by which the bidder commits to the execution of the services, plus the amount of [insert amount corresponding to VAT, in letters and in numbers] euros our USD for VAT, if applicable.

CONCEPT	BUDGET CONCEPT OFFERED (VAT excluded)	VALUES MAXIMUM ESTIMATED RECRUITMENT (VAT excluded)
GAP Analysis		**USD 95,000 exempt bidders or EUR 64.305,00 (excluding VAT) for non-exempt bidders**

Billing and payment will be always made under invoice and 30 days from invoice date by bank transfer.